Felbamate
Also known as: FELBAMA
Use
Felbamate is indicated for the treatment of epilepsy. The test helps in optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Patient pharmacokinetics may vary due to age, co-medications, and/or compromised renal function. Monitoring helps prevent adverse effects such as nausea, vomiting, dizziness, blurred vision, and ataxia. Felbamate use may increase the incidence of liver failure and aplastic anemia.
Special Instructions
The timing of specimen collection should be a pre-dose (trough) draw at steady-state concentration. Avoid use of separator tubes and gels.
Limitations
The test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration, although it is performed in a CLIA certified laboratory and is intended for clinical purposes.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 6899-9
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), gray (sodium fluoride/potassium oxalate).
Collection Instructions
Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube.
Patient Preparation
Pre-dose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 2 weeks |
| Frozen | 2 weeks |